Inotek to merge into gene therapy-focused Rocket Pharmaceuticals
By Michael Fitzhugh
Staff Writer
Staff Writer
Wednesday, September 13, 2017
Following the failure of Inotek Pharmaceuticals Corp.'s trabodenoson to move the needle in treating glaucoma, the company has found a new way forward: a proposed merger with New York-based gene therapy startup Rocket Pharmaceuticals Ltd.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.